Volastra Therapeutics

Volastra Therapeutics, a New York-based biotech firm, is at the forefront of developing innovative cancer therapies targeting chromosomal instability (CIN). Founded in 2019 by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., the company focuses on leveraging CIN, recognized as one of cancer's most exploitable vulnerabilities. With a slogan of "Clinical stage biotech developing a powerful new class of cancer therapies exploiting chromosomal instability," Volastra is advancing a pipeline of novel synthetic lethal and immune activating treatments. Notably, the company has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high CIN levels. Their dedication to pioneering cancer treatments has not gone unnoticed, with a recent $15.00M Venture Round investment received on 30 May 2024. As a prominent player in the Biotechnology industry, Volastra's groundbreaking work has the potential to revolutionize cancer treatment and attract more significant investment in the future.